Evaxion Biotech A/S

EVAX

NASDAQ

Healthcare

Biotechnology

Horsholm, DK46 employeesevaxion-biotech.com

$3.74

-0.20(-5.08%)

Mkt Cap $24M

$1.31

$11.01

52-Week Range

At a Glance

AI-generated

Evaxion Biotech A/S reported revenue of $7.5 million for FY 2025, up 125% from $3.3 million in FY 2024, driven by a $7.5 million upfront payment from MSD upon exercising its option to license EVX-B3 vaccine candidate, plus minor Gates Foundation grants.

6-K

Evaxion Biotech A/S convened its annual general meeting for 16 April 2026 at 14:00 CEST, proposing adoption of the 2025 audited annual report, carrying forward the loss, re-election of four board members, election of Jens Bitsch-Nørhave as new board member, re-election of EY as auditor, and authorizations for warrants up to DKK 11,900,000 and convertible loan notes up to DKK 73,500,000 nominal shares without pre-emptive rights.

$24M

Market Cap

$7M

Revenue

-$8M

Net Income

Employees46

Fundamentals

How The Business Makes Money

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Industry Biotechnology

Activity